Association Between Plasma D Dimer in Adult CAP and Severity of Inflammatory Response and Survival
NCT ID: NCT07199530
Last Updated: 2025-09-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
50 participants
OBSERVATIONAL
2025-06-23
2026-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
the study participants will be subjected to sampling for D dimer and calculation of CURB 65 score. this aims to find the relation between them
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
D-dimer is a fibrin degradation product that is elevated in many conditions associated with inflammation and coagulation activation, including pneumonia.
This is an observational study including a minimum of 50 patients with CAP
Patients who will be admitted at Chest department, or coming to the outpatient clinic Ain-Shams University Hospitals with CAP and have the following inclusions:
1. age ≥18 years
2. diagnosis of CAP based on clinical symptoms, laboratory findings, and radiological evidence.
3. Did not have any clinical or radiological signs suggesting Covid pneumonia Exclusion criteria Patients with a history of coagulation disorders, cancer, or other chronic diseases, or refusal to participate.
All patients will be subjected to the following: -
1. Full medical history, demographics
2. Thorough clinical examination.
3. laboratory values (including white blood cell count, CRP, and D-dimer), With pre and post sample known precautions (8).
4. Radiological findings (CXR).
5. Severity of illness (based on the CURB-65 score).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
only one group which will include patients with CAP to take a blood samplr for d dimer
Blood Product
blood sample for d dimer
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood Product
blood sample for d dimer
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. age ≥18 years
2. diagnosis of CAP based on clinical symptoms, laboratory findings, and radiological evidence.
Exclusion Criteria
* patients who have any clinical or radiological signs suggesting Covid pneumonia.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
hieba gamal ezz-elragal awad
assistant professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ain Shams University hospitals
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Hieba gamal Ezzelregal
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FAMSU R 135/2025
Identifier Type: -
Identifier Source: org_study_id